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 
Abstract— Objectives: To identify predictive biomarkers of 
CIMAvaxEGF success in the treatment of Non–Small Cell Lung 
Cancer Patients. Methods: Data from a clinical trial evaluating the 
effect on survival time of CIMAvax-EGF versus best supportive care 
were analysed retrospectively following the causal inference approach. 
Pre-treatment potential predictive biomarkers included basal serum 
EGF concentration, peripheral blood parameters and 
inmunocenescence biomarkers (The proportion of CD8 + CD28- T 
cells, CD4+ and CD8+ T cells, CD4/CD8 ratio and CD19+ B cells. 
The 33 patients with complete information were included. The 
predictive causal information (PCI) was calculated for all possible 
models. The model with a minimum number of predictors, but with 
high prediction accuracy (PCI>0.7) was selected. Good, rare and poor 
responder patients were identified using the predictive probability of 
treatment success. Results: The mean of PCI was increase from 0.486, 
when only one predictor is considered, to 0.98 using the multivariate 
approach with all predictors. The model considering the proportion of 
CD4+ T cell, basal EGF concentration, NLR, Monocytes and 
Neutrophils as predictors was selected (PCI>0.74). Patients predicted 
as good responder according to the pre-treatment biomarkers values 
treated with CIMAvax-EGF had a significant higher observed survival 
compared with control group (p=0.03). No difference was observed for 
bad responders. Conclusions: Peripheral blood parameters and 
inmunocenescence biomarkers together with basal EGF concentration 
in serum resulted good predictors of the CIMAvax-EGF success in 
advanced NSCLC. The study illustrates the application of a new 
methodology, based on causal inference, to evaluate of multivariate 
pre-treatment predictors. 
Keywords— CIMAvaxEGF, causal inference, predictive 
biomarkers, non-small-cell lung cancer.  
I. INTRODUCTION 
ANCER natural history involves interactions between 
tumor and host defense mechanisms. The therapeutic 
potential of host-specific and tumor-specific immune responses 
is well recognized and, after many years, immunotherapies 
directed at inducing or augmenting these responses are entering 
clinical practice. In particular, the epidermal growth-factor 
receptor superfamily is an attractive therapeutic target because 
it is commonly overexpressed in malignant disease, regulates 
many vital cellular processes, and seems to be a negative 
prognostic indicator. CIMAvax-EGF is a therapeutic anticancer 
vaccine, developed in Cuba under the concept that inducing 
EGF deprivation, which involves manipulating an individual’s 
immune response to release its own effector antibodies (Abs) 
against EGF, tumor size or its progression can be reduced. 
 
CIMAvax-EGF demonstrated to be safe and immunogenic in 
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advanced non-small cell lung cancer (NSCLC) patients in 
several clinical trials [1-5]. However, there is evidence of 
heterogeneous response to the vaccine. Patients with short-term 
and long-term survival were differentiated between those 
treated with CIMAvax-EGF [6].  In the phase II and phase III 
trials conducted, patient developed a ‘‘good antibody 
response’’  (anti-EGF antibody titers  ≥  1:4,000 sera dilution) 
seemed to have significantly better survival compared with 
patients who had lower anti-EGF antibody responses[1, 3, 4].  
On the other hand, correlation between EGF concentration at 
baseline and length of survival was observed since the phase I 
study [5]. The subsequent studies corroborated also this fact, 
vaccinated patients with serum basal EGF concentration >870 
pg/ml showed larger survival as compared with controls with 
the same EGF serum level [1, 2]. Furthermore, 
immunosenescence markers as the proportion of CD8+CD28− 
cells, CD4 cells, and the CD4/CD8 ratio after first-line 
chemotherapy was also associated with CIMAvax-EGF clinical 
benefit. All these studies point the importance given to the 
search of predictive biomarkers that allow the selection of 
patients who can receive a real benefit with the vaccine. 
 
Although several attempts have been done to find predictive 
biomarkers of clinical benefit of CIMAvax-EGF, always each 
potential predictor was evaluated separately. The univariate 
approach used has the advantage that is easy to interpret and use 
simple statistical techniques, comprehensible to the medical 
community. Nevertheless, a multivariate approach gives a 
much richer and realistic picture than looking at a single 
variable and provides a powerful test of significance to validate 
biomarkers compared to univariate techniques. Multivariate 
approach allows researchers to look at relationships between 
variables in an overarching way. 
 
The aim of this study is to evaluate multivariate predictors of 
CIMAvax-EGF therapeutic success using the causal inference 
approach.  
II. METHODS 
A. Data 
We analyzed data from patients with histologic evidence of 
Non-Small Cell Lung Cancer (NSCLC) stage IIIb-IV recruited 
for a controlled phase III trial 
(http://www.who.int/ictrp/network/rpcec/en/; Cuban Public 
Registry of Clinical Trials; Trial number   RPCEC00000161).  
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We selected all patients with measures of pre-treatment basal 
EGF concentration, peripheral blood parameters, inflammation 
and inmunocenescence biomarkers.  The methods and results of 
these trials have been reported elsewhere[1, 7]. Briefly, patients 
were randomized to either vaccine Arm (CIMAvaxEGF plus 
Best Supportive Care) or Control Arm (only Best Supportive 
Care). The eligible patients were those aged 18 years or older 
with histologically or cytological confirmed stage IIIb or IV 
NSCLC, and with an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 to 2. All patients had received 
4 to 6 cycles of platinum-based chemotherapy before random 
assignment and had finished first-line chemotherapy at least 4 
weeks before entering in the trial. Pregnancy or lactation, 
secondary malignancies, or history of hypersensitivity to 
foreign proteins rendered patients ineligible. The primary 
efficacy endpoint was the survival time, defined as elapsed time 
since trial inclusion to death.  
 
The potential pre-treatment predictive variables considered 
were basal serum EGF concentration, peripheral blood 
populations (absolute neutrophils, lymphocyte, monocytes and 
platelets counts, neutrophil-to-lymphocyte ratio and platelet-to-
lymphocyte ratio) and inmunocenescence biomarkers (The 
proportion of CD4 + T cells and CD4/CD8 ratio). We only 
included in this work data from 40 patients who had completed 
measures of the potential pre-treatment predictive variables..  
B. Modeling approach 
Calculation of the predictive causal inference association for 
all possible models 
Following the causal inference approach proposed by Alonso 
and colleagues [8], we analyzed each of our potential predictors 
separately, in a univariate way, and later all possible 
combinations of them. For all, the predictive causal information 
(PCI) was calculated. It was defined as the correlation between 
the treatment effect and the predictors. PCI indicate the 
prediction accuracy, i.e., how accurately one can predict the 
individual causal treatment effect on the true endpoint for a 
given individual, using his pre-treatment predictor 
measurements. The interpretation is similar to the widely used 
correlation coefficients. If PCI is exactly 1, that’s indicate a 
perfect prediction of the individual causal treatment effect using 
the values of predictors. The closer the values are to zero, the 
lower the model's ability to predict the real benefit of the patient 
from the values of the predictors. The prediction accuracy was 
classified according to the value of the PCI as negligible 
(PCI≤0.3), low accurate (0.3< PCI≤0.5), moderately accurate 
(0.5< PCI≤0.7), highly accurate (0.7< PCI ≤0.9) and very high 
(0.9< PCI ≤1). All calculation where performed using the R 
library EffectTreat. 
 
Selection of a model taking into account its complexity and 
prediction accuracy 
The inclusion of more predictors will always lead to an 
increase in information about the effect of individual causal 
treatment. However, measuring and collecting data on multiple 
predictors can increase the burden for clinical investigators, 
patients and generate higher costs. We propose to follow the 
criterion of parsimony, that is, to select a model with the correct 
amount of predictors necessary to explain the data well. Firstly, 
within the combinations with the same number of predictors, 
we select the one with the highest PCI value. Then we classify 
its accuracy according to the scale previously described. 
Finally, we chose the model with a minimum number of 
predictors (lowest complexity), but with all the PCI values 
above 0.7, that is, with a high prediction accuracy. 
 
Identification of good, rare and bad responders to the 
treatment 
The classic definition of responder (tumor reduction or 
complete remission) is modified in this investigation to adapt to 
the more general clinical situation. We define good responders 
as patients under the new treatment, who benefit from it. Their 
benefit is manifested in the fact that their value of the survival 
time is longer than that of patients with the same characteristics 
(predictive factors), randomized in the control group. The 
causal inference approach implies a comparison between what 
actually happened with the new treatment and what would have 
happened if the patient had received the control treatment. The 
key challenge is that it is not possible to observe both outputs 
simultaneously in the same patient and should be approximated 
with reference to a comparison group. In the methodology 
proposed by Alonso (2015), the authors introduce a sensitivity 
analysis to handle this problem. They assume a range of 
possible values for the correlation between the potential 
outcomes and for each correlation they estimate the probability 
of treatment success for an individual patient. Considering this, 
here an individual is classified as a good responder if all their 
probabilities of treatment success are estimated greater than 0.5. 
We define bad responders to be patients under the new 
treatment who are harmed by it, that is, if all the probabilities 
of treatment success are lower than 0.5. Consequently, rare-
responders would be patients who are neither good nor bad 
responders.  In this last group are the patients that depending on 
the correlation between the potential outcomes can have values 
of probability of treatment success above and below 0.5 
 
Subgroup analyses for survival benefit  
To show the heterogeneity in the response to CIMAvax-
EGF, the Kaplan Meier survival estimation was carried out in 
the good and poor responder patients. The log-rank test was 
used to compare the survival for the treated and control groups 
inside the subgroups identified by the biomarkers. 
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III. RESULTS 
Calculation of the predictive causal inference association 
for all possible models 
Predictive individual causal association was univariate 
evaluated for each predictor, along all possible “realities” for 
the correlation between potential outcomes. The mean, 
minimum and maximum values of PCI for each model, as well 
as the accuracy is shown in Table 1. Note that all univariate 
models were negligible or low accurate. The proportion of 
CD4+ cell was the best predictor in the univariate analysis with 
a PCI of 0.49. 
 
Table 1. Predictive Individual Causal Inference association 
(PCI) for each predictor.  
Predictors 
PCI 
mean (min-max) 
Basal EGF concentration 0.005 (0.003-0.008) 
Eosinophils 0.001 (0.001-0.002) 
Lymphocytes 0.007 (0.005-0.012) 
Neutrophils 0.030 (0.019-0.051) 
Platelets 0.036 (0.023-0.059) 
Monocytes 0.163 (0.108-0.259) 
NLR 0.025 (0.016-0.043) 
PLR 0.004 (0.003-0.008) 
Proportion of CD19+ B cell 0.053 (0.034-0.087) 
Proportion of CD8+ T cell 0.087 (0.062-0.127) 
Proportion of CD8-CD28- T cell 0.148 (0.098-0.239) 
CD4+/CD8+ ratio 0.443 (0.324-0.626) 
Proportion of CD4+ T cell 0.486 (0.353-0.694) 
 
Selection of a model taking into account its complexity and 
prediction accuracy 
The PCI values were calculated for the 8204 models defined 
considering all possible combinations of the biomarkers. The 
model with the 13, biomarkers reach a mean PCI value of 0.98 
indicating that prediction accuracy of the complete model is 
very high.  Figure 1 shows the increase in the values of PCI with 
the number of predictors. Note that from the model with 5 
predictors (Proportion of CD4+ T cell, basal EGF 
concentration, NLR, Monocytes and Neutrophils) a high 
accuracy is obtained. Importantly, the minimum PCI obtained 
with the 5-dimensional predictor (min= 0.74) already exceeds 
the maximum value obtained for the best univariate predictor 
(Proportion of CD4+ T cell, max Pred-ICA=0.69). This was the 
model selected. 
 
Figure 1. Predictive individual causal association by the best 
model according to the number of predictors: 1-proportion of 
CD4+ T cell, 2- proportion of CD4+ T cell and absolute 
monocytes counts, 3- proportion of CD4+ T cell, NLR and 
Neutrophils, 4- proportion of CD4+ T cell, NLR, Neutrophils 
and Eosinophils, 5- Proportion of CD4+ T cell, basal EGF 
concentration, NLR, Monocytes and Neutrophils, 6- Proportion 
of CD4+ T cell, Proportion of CD8+ T cell, basal EGF 
concentration, NLR, Monocytes and Neutrophils, 7- Proportion 
of CD4+ T cell, Proportion of CD8+ T cell, basal EGF 
concentration, NLR, Monocytes, Neutrophils and Eosinophils 
 
Identification of good, rare and bad responders to the 
treatment 
Using the selected model, we can compute the probability of 
treatment success for an individual patient. These probabilities 
are shown in Figure 2 in three different scenarios of predictor’s 
values. The probability of treatment success is higher than 0.5 
in all “realities” for the first imaginary patient, an individual 
with basal EGF concentration=1700, CD4+ T cells=65, 
CD4/CD8 ratio=3, NLR=2 and Neutrophils=55. This 
probability increases when the value of the correlation between 
the potential effect of the treatment and the effect of best 
supportive care (control) increases. This patient may be 
considered as a good responder to the treatment. For the second 
scenario, we considered a patient with basal EGF concentration 
=800, CD4+ T cells =60, CD4/CD8 ratio=3, NLR=1, 
Neutrophils=70. For this patient the treatment has the same 
probability of success as of failure. Finally, for the last scenario, 
a patient with lower values of basal EGF concentration in 
serum, low proportion of CD4+ T cell, and low NLR (basal 
EGF concentration =500, CD4+ T cells =20, CD4/CD8 ratio=1, 
NLR=0.5, Neutrophils=75) was considered. The probability of 
treatment success in this case is lower than 0.5 in all possible 
“realities”. This patient may be considered as a bad responder 
to the treatment. Using the Excel score sheet developed (see the 
supplement) one can calculate the expected individual causal 
treatment effect. Therefore, we classify all patients in three 
groups: good responders, rare and bad responders.  
  
  
 
 
Figure 2 Predictive probability of treatment success for three 
examples of a) Good responder (basal EGF 
concentration=1700, CD4+ T cells=65, CD4/CD8 ratio=3, 
NLR=2, Neutrophils=50), b) Rare (basal EGF concentration 
=900, CD4+ T cells =35, CD4/CD8 ratio=3, NLR=2, 
Neutrophils=55) and c) Bad responders (basal EGF 
concentration =200, CD4+ T cells =10, CD4/CD8 ratio=1, 
NLR=1, Neutrophils=60) to CIMAvax-EGF 
 
Subgroup analyses for survival benefit  
The survival curves for good and bad responders is shown in 
the Figure 3. A great difference is observed between the treated 
and control groups but for patients classified as good responders 
according to the model. Almost 50% of these patients resulted 
long term survivors (live more than 2 years), while no long term 
survivors were observed between patient received best 
supportive cares only. In contrast, patients predicted as bad 
responders had a survival time comparable to the controls with 
the similar biomarkers characteristics. 
 
 
Figure 3. Kaplan Meier survival curves for patient treated with 
CIMAvax-EGF and control for a) good responders, b) poor 
responders.  
IV. DISCUSSION 
Use e Together with the predictive biomarkers previously 
reported (T cell subpopulations and the EGF serum levels) our 
finding suggest, for the first time, the importance of the blood 
markers (NLR, Monocytes and Neutrophils) to predict the 
therapeutic success of CIMAvax-EGF. From the 
methodological point of view, the study shows the usefulness 
of the multivariate causal inference approach to identify a good 
combination of predictive biomarkers and to illustrate the 
application of this methodology for the identification of 
subgroups of advanced lung cancer patients with good, rare and 
bad probabilities of success with CIMAvax-EGF. 
 
Previous studies evaluating the biomarkers of 
CIMAvaxEGF, used a univariate approach and looked at a 
single biological phenomenon. On the one hand, there are 
studies reporting the role of the EGF circulating in blood in the 
success of CIMAvaxEGF and the relationship with the 
mechanism of action of this immunotherapy [1, 3]. They 
highlighted that the EGF level in patients’ sera could be 
simultaneously a biomarker of poor prognosis and a predictive 
factor of CIMAvax-EGF benefit. On the other hand, the 
biomarkers related to immunosenescence and its relationship 
with the CIMAvax-EGF therapeutic success was assessed by 
Saavedra and colleagues (2016). They found that patients 
treated with CIMAvax-EGF with CD4+ T cells counts greater 
than 40%, CD8+CD28− T cells counts lower than 24% and a 
CD4/ CD8 ratio >2 after first-line platinum-based 
chemotherapy, achieved a significantly large median survival, 
as compared to controls with the same phenotype. In these 
studies, the biomarkers, as is common in medical research, 
where dichotomized using the median or an optimal cut point. 
This follows the clinical practice of labelling individuals as 
having or not an attribute. Nevertheless, it is well known in the 
methodological literature that dichotomization of continuous 
variables introduces major problems include loss of 
information, reduction in power and uncertainty in defining the 
cut point [9]. The present study has as a strength that allows the 
analysis of the role of all these biomarkers jointly taking 
advantage of the continuous measurement scale. Moreover, it 
incorporates some markers of peripheral blood that have been 
related to the inflammatory process [10].  
 
Currently, most pre-treatment predictors of therapeutic 
success are evaluated using correlational techniques. 
Regression model, the most used method, is able to include 
prognostic variables as a main effect and predictive variables in 
an interaction with treatment variable. A statistically significant 
and large interaction effect usually indicates potential 
subgroups that may have different responses to the treatment. 
However, in the conventional regression method to specify the 
interaction term the knowledge of predictive variables is 
required in advance. Such pre-specification of a regression 
model usually fails to identify the correct subgroups due to 
large number of covariates and complex interactions among 
them. The methodology used here was introduced to overcome 
these problems [8].  
 
We recognize that there are limitations in the study because 
the small sample size and the possible biases inherent in any 
retrospective study. A new confirmatory study with a larger 
sample size is now being carried out to validate the predictive 
value of the biomarkers identified.  
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